Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective

Author： Brugaletta Salvatore Burzotta Francesco Sabaté Manel

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.6, 2009-04, pp. : 1047-1058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease

By Pothula A. Serebruany V.L. Gurbel P. McKenzie M.E. Atar D.

European Journal of Pharmacology, Vol. 402, Iss. 1, 2000-08 ,pp. : 1-10

Elsevier

Access to resources Recommend Favorite

Revascularization treatment of stable coronary artery disease

By Magro Michael Garg Scot Serruys Patrick W

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 195-212

Informa Healthcare

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease

By Salam Amar M Al Suwaidi Jassim

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1645-1658

Informa Healthcare

Access to resources Recommend Favorite

Secondary Prevention of Coronary Artery Disease with Antimicrobials: Current Status and Future Directions

By Muhlestein J.B.

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 2, 2002-02 ,pp. : 107-118

Adis International

Access to resources Recommend Favorite

Enoxaparin: A Review of its Clinical Potential in the Management of Coronary Artery Disease

By Noble S. Spencer C.M.

Drugs, Vol. 56, Iss. 2, 1998-08 ,pp. : 259-272

Adis International

Access to resources Recommend Favorite